Waldenström macroglobulinemia and relationship to immune deficiency.

Waldenstrom macroglobulinemia immune deficiency immunosuppression real-life experience relationship

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
11 2021
Historique:
pubmed: 5 6 2021
medline: 3 11 2021
entrez: 4 6 2021
Statut: ppublish

Résumé

Primary or secondary immune deficiency (ID) is a risk factor, although rare, to develop Waldenström macroglobulinemia (WM). We aimed to better understand the incidence of this occurrence in the real-life and the outcome of either entity. We conducted a review of 194 WM in the Poitou-Charentes registry and identified 7 (3.6%) with a prior history of ID. Across the 7 WM with ID, 4 progressed to active WM disease and required treatment for WM with a median time between WM diagnosis and the first treatment of 1.5 years (range 0-3). The median time from ID to WM occurrence was 8 years (1-18). WM could develop from ID, although a rare event. Our first action was to systematically decrease immunosuppression with long-term control of ID. Half of indolent WM remained indolent despite ID and for remaining WM none appeared of poor risk WM.

Identifiants

pubmed: 34085595
doi: 10.1080/10428194.2021.1907379
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2665-2670

Auteurs

Anthony Levy (A)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Stéphanie Guidez (S)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Céline Debiais (C)

Laboratoire d'Anatomie Pathologie, CHU, Poitiers, France.

Isabelle Princet (I)

Pharmacie Centrale, CHU, Poitiers, France.

Sabrina Bouyer (S)

Service d'Hématologie Biologique, CHU, Poitiers, France.

Elodie Dindinaud (E)

Service d'Hématologie Biologique, CHU, Poitiers, France.

Vincent Delwail (V)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Thomas Systchenko (T)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Niels Moya (N)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Cécile Gruchet (C)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Florence Sabirou (F)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Arthur Bobin (A)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Hélène Gardeney (H)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Laly Nsiala (L)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Laura Cailly (L)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Gaëlle Olivier (G)

Service de Médecine Interne, Niort, France.

Carine Motard (C)

Service de Médecine Interne, Niort, France.

Emmanuel Fleck (E)

Service d'Onco-Hématologie, La Rochelle, France.

Anne Corby (A)

Service d'Onco-Hématologie, La Rochelle, France.

Christophe Roul (C)

Service d'Onco-Hématologie, La Rochelle, France.

Guillaume Denis (G)

Service de Médecine Interne, Rochefort, France.

Céline Dieval (C)

Service de Médecine Interne, Rochefort, France.

Xavier Leleu (X)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Cécile Tomowiak (C)

Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH